RATIONALE: Interval timing in the free-operant psychophysical procedure is sensitive to the monoamine-releasing agent d-amphetamine, the D(2)-like dopamine receptor agonist quinpirole, and the D(1)-like agonist 6-chloro-2,3,4,5-tetrahydro-1-phenyl-1H-3-benzepine (SKF-81297). The effect of d-amphetamine can be antagonized by selective D(1)-like and 5-HT(2A) receptor antagonists. It is not known whether d-amphetamine's effect requires an intact 5-hydroxytryptamine (5-HT) pathway. OBJECTIVE: The objective of this study was to examine the effects of d-amphetamine, quinpirole, and SKF-81297 on timing in intact rats and rats whose 5-hydroxytryptaminergic (5-HTergic) pathways had been ablated. MATERIALS AND METHODS: Rats were trained under the free-operant psychophysical procedure to press levers A and B in 50-s trials in which reinforcement was provided intermittently for responding on A in the first half, and B in the second half of the trial. Percent responding on B (%B) was recorded in successive 5-s epochs of the trials; logistic functions were fitted to the data for derivation of timing indices (T(50), time corresponding to %B = 50%; Weber fraction). The effects of d-amphetamine (0.4 mg kg(-1) i.p.), quinpirole (0.08 mg kg(-1) i.p.), and SKF-81297 (0.4 mg kg(-1) s.c.) were compared between intact rats and rats whose 5-HTergic pathways had been destroyed by intra-raphe injection of 5,7-dihydroxytryptamine. RESULTS: Quinpirole and SKF-81297 reduced T(50) in both groups; d-amphetamine reduced T(50) only in the sham-lesioned group. The lesion reduced 5-HT levels by 80%; catecholamine levels were not affected. CONCLUSIONS: d-Amphetamine's effect on performance in the free-operant psychophysical procedure requires an intact 5-HTergic system. 5-HT, possibly acting at 5-HT(2A) receptors, may play a 'permissive' role in dopamine release.
RATIONALE: Interval timing in the free-operant psychophysical procedure is sensitive to the monoamine-releasing agent d-amphetamine, the D(2)-like dopamine receptor agonist quinpirole, and the D(1)-like agonist 6-chloro-2,3,4,5-tetrahydro-1-phenyl-1H-3-benzepine (SKF-81297). The effect of d-amphetamine can be antagonized by selective D(1)-like and 5-HT(2A) receptor antagonists. It is not known whether d-amphetamine's effect requires an intact 5-hydroxytryptamine (5-HT) pathway. OBJECTIVE: The objective of this study was to examine the effects of d-amphetamine, quinpirole, and SKF-81297 on timing in intact rats and rats whose 5-hydroxytryptaminergic (5-HTergic) pathways had been ablated. MATERIALS AND METHODS:Rats were trained under the free-operant psychophysical procedure to press levers A and B in 50-s trials in which reinforcement was provided intermittently for responding on A in the first half, and B in the second half of the trial. Percent responding on B (%B) was recorded in successive 5-s epochs of the trials; logistic functions were fitted to the data for derivation of timing indices (T(50), time corresponding to %B = 50%; Weber fraction). The effects of d-amphetamine (0.4 mg kg(-1) i.p.), quinpirole (0.08 mg kg(-1) i.p.), and SKF-81297 (0.4 mg kg(-1) s.c.) were compared between intact rats and rats whose 5-HTergic pathways had been destroyed by intra-raphe injection of 5,7-dihydroxytryptamine. RESULTS:Quinpirole and SKF-81297 reduced T(50) in both groups; d-amphetamine reduced T(50) only in the sham-lesioned group. The lesion reduced 5-HT levels by 80%; catecholamine levels were not affected. CONCLUSIONS:d-Amphetamine's effect on performance in the free-operant psychophysical procedure requires an intact 5-HTergic system. 5-HT, possibly acting at 5-HT(2A) receptors, may play a 'permissive' role in dopamine release.
Authors: S S al-Zahrani; M Y Ho; D N Velazquez Martinez; M Lopez Cabrera; C M Bradshaw; E Szabadi Journal: Psychopharmacology (Berl) Date: 1996-10 Impact factor: 4.530
Authors: T H C Cheung; G Bezzina; K Asgari; S Body; K C F Fone; C M Bradshaw; E Szabadi Journal: Psychopharmacology (Berl) Date: 2006-03-15 Impact factor: 4.530
Authors: Robert B Moreland; Masaki Nakane; Diana L Donnelly-Roberts; Loan N Miller; Renjie Chang; Marie E Uchic; Marc A Terranova; Earl J Gubbins; Rosalind J Helfrich; Marian T Namovic; Odile F El-Kouhen; Jeffrey N Masters; Jorge D Brioni Journal: Biochem Pharmacol Date: 2004-08-15 Impact factor: 5.858
Authors: Zackary A Cope; Adam L Halberstadt; Jordy van Enkhuizen; Aaron D Flynn; Michelle Breier; Neal R Swerdlow; Mark A Geyer; Jared W Young Journal: Psychopharmacology (Berl) Date: 2016-08-17 Impact factor: 4.530
Authors: Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson Journal: Neurosci Biobehav Rev Date: 2012-10-12 Impact factor: 8.989
Authors: Adam L Halberstadt; Ivan S Sindhunata; Kees Scheffers; Aaron D Flynn; Richard F Sharp; Mark A Geyer; Jared W Young Journal: Neuropharmacology Date: 2016-03-25 Impact factor: 5.250
Authors: Ting Carrie Yan; Julia A Dudley; Ruth K Weir; Ewelina M Grabowska; Yolanda Peña-Oliver; Tamzin L Ripley; Stephen P Hunt; David N Stephens; S Clare Stanford Journal: PLoS One Date: 2011-03-07 Impact factor: 3.240
Authors: Hugo Sanchez-Castillo; Kathleen M Taylor; Ryan D Ward; Diana B Paz-Trejo; Maria Arroyo-Araujo; Oscar Galicia Castillo; Peter D Balsam Journal: Int J Comp Psychol Date: 2015
Authors: L Valencia-Torres; C M Olarte-Sánchez; S Body; T H C Cheung; K C F Fone; C M Bradshaw; E Szabadi Journal: Behav Brain Res Date: 2012-08-16 Impact factor: 3.332